Effect of resveratrol on experimental non‐alcoholic fatty liver disease depends on severity of pathology and timing of treatment

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Gastroenterology and Hepatology

• Publication date

  2016-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jgh.13151PMID 26312773
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Extrahepatic Complications of Nonalcoholic Fatty Liver Disease.

  2016cited by this paper
• High‐fat and high‐cholesterol diet rapidly induces non‐alcoholic steatohepatitis with advanced fibrosis in Sprague–Dawley rats

  2015cited by this paper
• Resveratrol Does Not Influence Metabolic Risk Markers Related to Cardiovascular Health in Overweight and Slightly Obese Subjects: A Randomized, Placebo-Controlled Crossover Trial

  2015cited by this paper
• Effect of resveratrol on experimental non-alcoholic steatohepatitis.

  2015cited by this paper
• Resveratrol and obesity: Can resveratrol relieve metabolic disturbances?

  2015cited by this paper
• Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes.

  2015cited by this paper
• P1044 : Randomised, placebo-controlled clinical trial: Long-term resveratrol treatment for non-alcoholic fatty liver disease

  2015cited by this paper
• Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.

  2015cited by this paper
• Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease.

  2014cited by this paper
• Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.

  2014cited by this paper
• Extrahepatic complications of nonalcoholic fatty liver disease

  2014cited by this paper
• Resveratrol and cardiovascular health--promising therapeutic or hopeless illusion?

  2014cited by this paper
• The resveratrol fiasco.

  2014cited by this paper
• Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation.

  2014cited by this paper
• Resveratrol Metabolism in a Non-Human Primate, the Grey Mouse Lemur (Microcebus murinus), Using Ultra-High-Performance Liquid Chromatography–Quadrupole Time of Flight

  2014cited by this paper
• Resveratrol does not benefit patients with nonalcoholic fatty liver disease.

  2014cited by this paper
• Ultra high performance liquid chromatography-quadrupole-time of flight analysis for the identification and the determination of resveratrol and its metabolites in mouse plasma.

  2013cited by this paper
• Resveratrol attenuates oxidative stress and prevents steatosis and hypertension in obese rats programmed by early weaning.

  2013cited by this paper
• Semi-preparative isolation of dihydroresveratrol-3-O-β-d-glucuronide and four resveratrol conjugates from human urine after oral intake of a resveratrol-containing dietary supplement.

  2013cited by this paper
• High-Dose Resveratrol Supplementation in Obese Men

  2013cited by this paper
• Sulfate Metabolites Provide an Intracellular Pool for Resveratrol Generation and Induce Autophagy with Senescence

  2013cited by this paper
• Nonalcoholic fatty liver disease in Asia: A story of growth

  2013cited by this paper
• Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats.

  2013cited by this paper
• Evolving aspects of liver transplantation for nonalcoholic steatohepatitis

  2013cited by this paper
• Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet.

  2012cited by this paper
• Pilot study of resveratrol in older adults with impaired glucose tolerance.

  2012cited by this paper
• Are sirtuins viable targets for improving healthspan and lifespan?

  2012cited by this paper
• Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans.

  2011cited by this paper
• Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress

  2011cited by this paper
• Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients.

  2010cited by this paper
• Steady-State Pharmacokinetics and Tolerability of Trans-Resveratrol 2000mg Twice Daily with Food, Quercetin and Alcohol (Ethanol) in Healthy Human Subjects

  2010cited by this paper
• Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis.

  2010cited by this paper
• Safety studies conducted on high-purity trans-resveratrol in experimental animals.

  2009cited by this paper
• Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase

  2008cited by this paper
• Resveratrol inhibits nonalcoholic fatty liver disease in rats

  2008cited by this paper
• Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet.

  2008cited by this paper
• Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.

  2007cited by this paper
• Dose translation from animal to human studies revisited

  2007cited by this paper
• Long‐term follow‐up of patients with NAFLD and elevated liver enzymes

  2006cited by this paper
• Resveratrol improves health and survival of mice on a high-calorie diet

  2006cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• Uncoupled and surviving: individual mice with high metabolism have greater mitochondrial uncoupling and live longer

  2004cited by this paper
• Rodent nutritional model of non‐alcoholic steatohepatitis: Species, strain and sex difference studies

  2003cited by this paper
• Effect of dietary fat content on the incidence of obesity among ad libitum fed mice.

  1985cited by this paper

• Dietary resveratrol alleviates liver and intestinal injury in ducks under cage rearing system

  2025cites this paper
• Impact of gut microbiota on metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and therapeutic advances

  2024cites this paper
• The monomer of resveratrol butyrate ester ameliorates obesity and gut microbiota in high-fat diet rats

  2024cites this paper
• Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?

  2024cites this paper
• Sirtuins, resveratrol and the intertwining cellular pathways connecting them.

  2023cites this paper
• UNIVERSIDADE DE SÃO PAULO FACULDADE DE MEDICINA DE RIBEIRÃO PRETO

  2022cites this paper
• Preparation, Characterization, and In Vitro/In Vivo Evaluation of 3-O-β-D-Galactosylated Resveratrol-Loaded Polydopamine Nanoparticles

  2021cites this paper
• Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.

  2020cites this paper
• The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease.

  2020cites this paper
• Resveratrol Metabolites Are Able to Reduce Steatosis in Cultured Hepatocytes

  2020cites this paper
• Synthesis, cytotoxicity and liver targeting of 3‐O‐β‐D‐Galactosylated Resveratrol

  2019cites this paper
• Involvement of 5′AMP-Activated Protein Kinase (AMPK) in the Effects of Resveratrol on Liver Steatosis

  2018cites this paper
• Preserved liver regeneration capacity after partial hepatectomy in rats with non-alcoholic steatohepatitis

  2018cites this paper
• Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging.

  2017cites this paper
• Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats

  2017cites this paper
• Long‐Term Ethanol Exposure Decreases the Endotoxin‐Induced Hepatic Acute Phase Response in Rats

  2017cites this paper
• Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis

  2016cites this paper
• Low-dose resveratrol supplementation on heart rate variability in hypertensive volunteers: a controlled double-blind trial

  2016cites this paper
• Acetylation of lysine 109 modulates pregnane X receptor DNA binding and transcriptional activity.

  2016cites this paper
• Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy

  2015cites this paper